Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Follicular thyroid cancer
The overall 5-year survival rate for follicular thyroid cancer is 91%, and the 10-year survival rate is 85%.